O	0	4	Bone
O	5	13	turnover
O	14	21	markers
O	22	25	and
O	26	33	insulin
O	33	34	-
O	34	38	like
O	39	45	growth
O	46	52	factor
O	53	63	components
O	64	66	in
O	67	77	metastatic
O	78	84	breast
O	85	91	cancer
O	91	92	:
O	93	100	results
O	101	105	from
O	106	107	a
O	108	118	randomised
O	119	124	trial
O	125	127	of
B-intervention	128	138	exemestane
O	139	141	vs
B-control	142	151	megestrol
I-control	152	159	acetate
O	159	160	.

O	161	164	The
O	165	168	aim
O	169	171	of
O	172	176	this
O	177	187	randomised
O	188	193	study
O	194	197	was
O	198	200	to
O	201	208	compare
O	209	212	the
O	213	220	effects
O	221	223	of
O	224	234	progestins
O	235	238	and
O	239	248	aromatase
O	249	261	inactivators
O	262	264	on
O	265	269	bone
O	270	281	remodelling
O	282	289	markers
O	290	293	and
O	294	297	the
O	298	308	components
O	309	311	of
O	312	319	insulin
O	319	320	-
O	320	324	like
O	325	331	growth
O	332	338	factor
O	339	341	in
B-eligibility	342	350	patients
I-eligibility	351	355	with
I-eligibility	356	366	metastatic
I-eligibility	367	373	breast
I-eligibility	374	380	cancer
O	380	381	.

O	382	388	Within
O	389	392	the
O	393	402	framework
O	403	405	of
O	406	407	a
O	408	413	large
O	414	415	(
B-total-participants	415	418	769
O	419	427	patients
O	427	428	)
O	428	429	,
O	430	440	randomised
O	441	447	double
O	447	448	-
O	448	453	blind
O	454	462	clinical
O	463	468	trial
O	469	478	comparing
O	479	489	exemestane
O	490	491	(
O	491	494	EXE
O	494	495	)
O	496	500	with
O	501	510	megestrol
O	511	518	acetate
O	519	520	(
O	520	522	MA
O	522	523	)
O	523	524	,
O	525	530	serum
O	531	533	17
O	534	538	beta
O	538	539	-
O	539	548	estradiol
O	549	550	(
O	550	552	E2
O	552	553	)
O	553	554	,
O	555	562	estrone
O	563	564	(
O	564	566	E1
O	566	567	)
O	567	568	,
O	569	576	estrone
O	577	585	sulphate
O	586	587	(
O	587	590	E1S
O	590	591	)
O	591	592	,
O	593	597	bone
O	598	606	alkaline
O	607	618	phosphatase
O	619	620	(
O	620	623	BAP
O	623	624	)
O	624	625	,
O	626	633	carboxy
O	633	634	-
O	634	642	terminal
O	643	648	cross
O	648	649	-
O	649	656	linking
O	657	668	telopeptide
O	669	671	of
O	672	676	type
O	677	678	I
O	679	687	collagen
O	688	689	(
O	689	693	ICTP
O	693	694	)
O	695	698	and
O	699	702	the
O	703	713	components
O	714	716	of
O	717	724	insulin
O	724	725	-
O	725	729	like
O	730	736	growth
O	737	743	factor
O	744	745	(
O	745	748	IGF
O	748	749	)
O	750	756	family
O	757	758	(
O	758	761	IGF
O	761	762	-
O	762	763	1
O	763	764	,
O	765	768	IGF
O	768	769	-
O	769	770	2
O	771	774	and
O	775	780	IGFBP
O	780	781	-
O	781	782	3
O	782	783	)
O	784	788	were
O	789	799	determined
O	800	802	in
B-total-participants	803	805	53
O	806	814	patients
O	815	816	(
B-intervention-participants	816	818	24
O	819	829	randomised
O	830	832	to
O	833	836	EXE
O	837	840	and
B-control-participants	841	843	29
O	844	854	ramdomised
O	855	857	to
O	858	860	MA
O	860	861	)
O	861	862	.

O	863	868	After
O	869	874	eight
O	875	880	weeks
O	881	883	of
O	884	893	treatment
O	893	894	,
O	895	899	both
B-outcome	900	904	ICTP
O	905	908	and
B-outcome	909	912	BAP
O	913	922	increased
O	923	924	(
O	924	925	p
O	926	927	<
O	928	929	0
O	929	930	.
O	930	932	01
O	932	933	)
O	934	936	in
O	937	940	the
O	941	944	EXE
O	945	950	group
O	950	951	,
O	952	955	but
O	956	960	only
O	961	965	ICTP
O	966	968	in
O	969	972	the
O	973	975	MA
O	976	981	group
O	982	983	(
O	983	984	p
O	985	986	<
O	987	988	0
O	988	989	.
O	989	991	03
O	991	992	)
O	992	993	.

O	994	997	The
O	998	999	8
O	999	1000	-
O	1000	1004	week
B-outcome	1005	1016	suppression
I-outcome	1017	1019	of
I-outcome	1020	1022	E2
I-outcome	1023	1026	and
I-outcome	1027	1030	E1S
O	1031	1034	was
O	1035	1039	more
O	1040	1050	pronounced
O	1051	1053	in
O	1054	1057	the
O	1058	1061	EXE
O	1062	1067	group
O	1068	1069	(
O	1069	1071	to
O	1071	1072	,
O	1073	1085	respectively
O	1085	1086	,
O	1087	1089	11
O	1089	1090	.
O	1090	1091	2
O	1091	1092	%
O	1093	1096	and
O	1097	1098	9
O	1098	1099	.
O	1099	1100	9
O	1100	1101	%
O	1102	1104	of
O	1105	1113	baseline
O	1114	1120	values
O	1120	1121	)
O	1122	1126	than
O	1127	1129	in
O	1130	1133	the
O	1134	1136	MA
O	1137	1142	group
O	1143	1144	(
O	1144	1146	33
O	1146	1147	.
O	1147	1148	1
O	1148	1149	%
O	1150	1153	and
O	1154	1156	29
O	1156	1157	.
O	1157	1158	7
O	1158	1159	%
O	1159	1160	)
O	1160	1161	.

B-outcome	1162	1165	IGF
I-outcome	1165	1166	-
I-outcome	1166	1167	1
I-outcome	1168	1177	increased
O	1178	1179	(
O	1179	1180	p
O	1181	1182	<
O	1183	1184	0
O	1184	1185	.
O	1185	1187	01
O	1187	1188	)
O	1189	1191	in
O	1192	1196	both
O	1197	1203	groups
O	1203	1204	,
O	1205	1208	but
O	1209	1213	more
O	1214	1216	so
O	1217	1219	in
O	1220	1223	the
O	1224	1232	patients
O	1233	1240	treated
O	1241	1245	with
O	1246	1248	MA
O	1248	1249	.

B-outcome	1250	1258	Estrogen
I-outcome	1259	1265	levels
O	1266	1276	negatively
O	1277	1287	correlated
O	1288	1292	with
O	1293	1297	ICTP
O	1298	1300	in
O	1301	1305	both
O	1306	1312	groups
O	1312	1313	,
O	1314	1317	but
O	1318	1322	were
O	1323	1326	not
O	1327	1334	related
O	1335	1337	to
O	1338	1341	BAP
O	1342	1344	in
O	1345	1351	either
O	1351	1352	.

O	1353	1356	IGF
O	1356	1357	-
O	1357	1358	1
O	1359	1369	negatively
O	1370	1380	correlated
O	1381	1385	with
O	1386	1395	estrogens
O	1396	1398	in
O	1399	1403	both
O	1404	1410	groups
O	1410	1411	.

O	1412	1415	The
O	1416	1423	results
O	1424	1426	of
O	1427	1431	this
O	1432	1437	study
O	1438	1446	indicate
O	1447	1451	that
O	1452	1456	anti
O	1456	1457	-
O	1457	1466	aromatase
O	1467	1474	therapy
O	1475	1477	is
O	1478	1488	associated
O	1489	1493	with
O	1494	1503	increased
O	1504	1514	osteoclast
O	1515	1523	activity
O	1523	1524	,
O	1525	1528	and
O	1529	1536	suggest
O	1537	1540	the
O	1541	1550	existence
O	1551	1553	of
O	1554	1562	possible
O	1563	1575	differential
O	1576	1583	effects
O	1584	1586	of
O	1587	1596	different
O	1597	1605	hormonal
O	1606	1615	therapies
O	1616	1618	on
O	1619	1623	bone
O	1624	1635	remodelling
O	1636	1643	markers
O	1644	1654	regardless
O	1655	1657	of
O	1658	1661	the
O	1662	1670	estrogen
O	1671	1682	suppression
O	1683	1690	induced
O	1691	1693	by
O	1694	1697	EXE
O	1697	1698	.
